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Abstract
Background: Fractures of the extremities are often complicated by a variable degree of swelling secondary to
hemorrhage and soft tissue injury. Patients typically require up to 7 days of inpatient bed rest and elevation to
reduce swelling to an acceptable level for operative treatment with internal fixation. Alternatively, an intermittent
pneumatic compression device, such as the Vascular Impulse Technology (VIT) system, can be used at the
injured extremity to reduce the posttraumatic swelling. The VIT system consists of a pneumatic compressor that
intermittently rapidly inflates a bladder positioned under the arch of the hand or the foot, which results in
compression of the venous hand or foot plexus. That intermittent compression induces an increased venous
velocity and aims to reduce the soft tissue swelling of the affected extremity.
Methods/design: The VIT study is a prospective, monocenter, randomized controlled trial to compare the VIT
system with elevation in the treatment of posttraumatic swelling in the case of a fracture of the upper and lower
extremity. This study will include 280 patients with fractures of the upper and the lower extremity with nine
different injury types. For each of the nine injury types a separate randomization to the two intervention groups
(VIT group or control group) will be performed. The primary outcome parameter is the time taken for the swelling
to resolve sufficiently to permit surgery. A separate analysis for each of the nine injury types will be performed.
Discussion: In the proposed study, the effectiveness of the VIT system in the treatment of posttraumatic swelling
of upper and lower extremity fractures will be evaluated.
Trial registration: German Clinical Trial Register, No. DRKS00010510. Registered on 17 July 2016.
Keywords: Posttraumatic swelling, Elevation, Vascular impulse, Cryotherapy, Upper extremity, Lower extremity,
Intermittent pneumatic compression
Background
Background and rationale
Fractures of the upper and the lower extremity with in-
volvement of the joint are, in general, associated with
damage to the articular surface. Operative treatment
with open reduction and internal fixation is, therefore,
recommended for most of these fractures [1–6].
However, the treatment is often complicated by a vari-
able degree of swelling secondary to hemorrhage and
soft tissue injury [7–9]. Many of these fractures develop
severe swelling that precludes operative intervention
until adequate edema resolution has commenced [8, 9].
Patients typically require up to 7 days of inpatient bed
rest and elevation of the injured extremity to reduce
swelling to an acceptable level for operative treatment
with internal fixation [9]. Postoperative swelling of the
soft tissue is often responsible for complications, such as
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compartment syndrome, or local wound problems such
as skin necrosis or wound infection [10]. Beside this, the
perioperative swelling of the soft tissue is often accom-
panied by pain leading to prolonged immobilization and
the need for strong painkillers with their associated
complications. Delay in surgery impacts the patient in
the short term but also increases the burden on an
orthopedic inpatient trauma unit by prolonging the pre-
operative interval and total hospital stay [11].
Numerous interventions have been developed to con-
trol soft tissue swelling including elevation, compressive
dressings and splint immobilization [12–15]. More re-
cently, cryotherapy and intermittent pneumatic com-
pression (IPC) devices have been employed. The IPC
devices were first described in the medical literature in
1992 [16]. The main application area of these devices is
as antithrombotic therapy, and many reports have been
published to prove their antithrombotic effect [16–19].
Beside this, some IPC devices have different pump char-
acteristics but generally tend to rapidly inflate to a pres-
sure of approximately 100 mmHg in less than half a
second (Fig. 1). These systems have been shown to
stimulate venous return in the immobile lower limb as
effectively as walking [20].
Several studies have shown each of these to be effect-
ive in reducing edema faster than simple elevation and
immobilization [20, 21]. The use of an impulse foot-
pump system has previously been shown to reduce
edema by means of measurement of ankle and toe girths
[10, 11, 20]. The clinical advantages of these devices
have been determined in the treatment of ankle fractures
and calcaneal fractures [10, 11, 13, 14, 20]. The
hospitalization period and surgical site infections were
reduced in the patients who received the impulse foot-
pump system compared to the control group with eleva-
tion. However, the effectiveness of the impulse foot-
pump system has not yet been investigated in detail, as
complications such as postoperative skin necrosis and
compartment syndrome, and the amount of pain medi-
cation required have not been determined. Furthermore,
data for the impulse foot-pump system are only available
for its use in the treatment of ankle and calcaneal
fractures.
Preliminary data
One randomized controlled trial that included 54 pa-
tients with ankle fractures compared an impulse foot-
pump system with elevation and plaster in the treatment
of preoperative swelling [20]. The results of this trial
showed a significant reduction in time taken for ankle
swelling to settle prior to surgery in the patients using
the impulse system, together with a reduction in wound
and skin complications (11% versus 44%; p < 0.01) and
final preoperative ankle swelling (13 mm ± 13 versus
24 mm ± 17; p = 0.03). This study was the first to address
the issue of whether the impulse foot-pump system has
preoperative clinical value in an unselected group of pa-
tients with ankle fractures. This study is limited by the
fact, that only patients with ankle fractures have been in-
cluded and that the impulse system was only used in
preoperative management. The authors, therefore, con-
cluded that a further randomized controlled trial would
be useful to prove the additional benefit in continuing
foot-pump therapy in the postoperative phase.
Another study analyzing the effectiveness of the im-
pulse system was published in 2013 [11]; Dodds et al. re-
ported about 64 patients with closed ankle fractures
using the impulse system prior to surgery. These pa-
tients were compared with a retrospective control group
of 73 consecutive patients with closed ankle fractures
managed surgically in the same unit immediately prior
to the implementation of the impulse device study. The
results of this study have shown that the median length
of time to surgery, hospital stay duration and surgical
site infections were significantly reduced in the study
group as compared to the control group. This study is
limited by the retrospective nature of the control group.
Furthermore, more than half of the patients in the con-
trol group and in the study group had an isolated frac-
ture of the medial or lateral malleolus. These fractures
are benign regarding soft tissue swelling and do not re-
quire special treatment for swelling in general.
There are five more studies available in the medical lit-
erature that examined the clinical advantage of impulse
foot-pump devices and these were published between
1993 and 2000 [10, 13, 14, 21, 22]. These studies have
significant limitations, as only patients with fractures of
the ankle and the calcaneus have been included. Even if
the impulse foot- or hand-pump systems can be used in
fractures of the upper extremity and the tibial head, tib-
ial shaft and tibial pilon, there are no studies available
for these anatomical regions. In 2008, Khanna et al.
Fig. 1 Schematic illustration of the application and the mechanism
of the VADOPlex foot-pump system (with kind permission of the Fa.
OPED, http://oped-international.com/)
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conducted a comprehensive review of the evidence for
the use of IPC devices in the healing of fractures and
soft tissue injuries [23]. They concluded that the number
of subjects in human studies is small and that adequately
powered randomized controlled trials in humans are
needed to produce stronger evidence that is clinically
relevant.
Due to the methodological and clinical limitations of
the available studies, a prospective, randomized con-
trolled trial including a variety of injuries that have
undergone both pre and postoperative assessment is
needed to confirm the observed findings for both the
lower and upper extremities. In addition, the design of
the impulse foot- and hand-pump system has been
renewed (VADOPlex, Vascular Impulse Technology
(VIT) system, Fa. OPED, Fig. 1) and data are not yet
available for the latest generation of this system.
Objectives and hypotheses
The primary study parameter is the time to operability
of the injured extremity with respect to the surrounding
soft tissue. The primary hypothesis of this study is that
patients using the VIT system can receive surgical treat-
ment 2 days earlier than patients with elevation due to
faster reduction of soft tissue swelling. As mentioned be-
fore, the only available data in the medical literature re-
garding the use of the VIT system pertain to the
treatment of ankle and calcaneal fractures. Therefore,
the primary study hypothesis can only be investigated in
patients with fractures of the ankle, calcaneus and tibial
pilon.
Methods/design
Design of the study and setting
A prospective, monocenter, randomized controlled trial
with a parallel-group design is planned to show super-
iority of the VIT system compared to elevation of the in-
jured extremity. This study will enroll participants with
distinct injury patterns that are associated with severe
soft tissue swelling. The study center is a level-I Trauma
Center in Germany (BG Trauma Center Ludwigshafen).
Trial design and management are the responsibility of
the participating trauma center; biostatistical planning
and analysis will be performed by the Institute of Med-
ical Biometry and Informatics, University of Heidelberg.
Screening
Patients with injury of the lower extremity (fractures of
the tibial head, tibial shaft or tibial pilon, ankle, calca-
neus) or of the upper extremity (fracture of the proximal
humerus, distal humerus, distal radius or dislocation of
the elbow) that cannot be treated surgically within the
first day due to soft tissue swelling will be recruited for
this trial. After being informed about the study and its
potential risks, all individuals with an appropriate injury
pattern will be consecutively screened for eligibility ac-
cording to the inclusion and exclusion criteria until the
recruitment period is over.
Subject inclusion criteria
 Patients older than 17 years and younger than
81 years of age
 Written informed consent provision
 One of the following nine injury types with the
need for a preoperative inpatient treatment and
the need for subsequent open reduction and
internal fixation (fractures are classified according
to the Comprehensive Classification of the
OTA/AO [24]):
 Intra-articular calcaneal fracture
 Ankle fracture type 44B/C
 Tibial pilon fracture type 43B/C
 Distal radius fracture type 23/C
 Simple/complex elbow dislocation
 Distal humerus fracture type 13B/C
 Proximal humerus fracture
 Tibial head fracture type 41B/C
 Tibial shaft fracture
Subject exclusion criteria
 Patients younger than 18 years or older than
80 years of age
 Injury of the contralateral extremity
 Open fracture/dislocation
 Infection
 Lack of written informed consent
 Severe heart failure
 Acute phlebitis
 Acute thrombosis or pulmonary embolism
 Local problems of the skin (necrosis, bladder)
 Drug abuse
 Serving a gaol sentence
 Pregnancy
 Participation in another interventional trial
with interference of intervention and outcome
of this study
Patients will be informed about the details of the
study. Informed consent comprises a description of the
procedures and objectives of the study and the follow-up
period. Patients will be informed that participation is
completely voluntary. Participation does not confer the
patient with any advantages and nonparticipation does
not disadvantage the patient in any way. The use by the
trial of an already-accredited and CE-certified product
will be explained in detail. Potential adverse events
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regarding the application of the VIT system will also be
explained. The participants must provide their consent
for the study and for the follow-up. Participants will be
instructed to report any exceptional events immediately
to the study center. Screening will be performed by the
principal investigator or the subinvestigator. A Case
Report Form (CRF) will be prepared and will be used for
the whole investigation.
Randomization
For each of the nine injury types a separate randomization
to the two intervention groups (VIT group or control
group) will be performed. The randomization numbers
will be allocated in balanced blocks with varying size
(permuted blocks) in a 1:1 ratio using the web-based
software “Randoulette” provided by the Institute of Med-
ical Informatics, Statistics and Documentation of the
Medical University of Munich (https://wwwapp.ibe.med.
uni-muenchen.de/randoulette/index.jsp). This software al-
lows different randomization methods to be chosen as
well as different sets of parameters for the chosen method.
To avoid any potential of predicting the group allocation
of future patients, the block length is recorded in a separ-
ate document that is withheld from the study site.
In addition, persons with the right to randomize with
the software described above do not have the right to read
or edit the randomization design chosen within the soft-
ware. The software stores the result of randomization and
the patient’s characteristics as well as the name of the per-
son who randomized and the randomization date in a sep-
arate file, and only authorized persons can download this
file. Patients are randomized on the day of inclusion in the
study. Blinding of the patients and the assessors is unfeas-
ible. The investigators will perform the assessment accord-
ing to trial criteria.
Interventions
The patients included will be randomized in a 1:1 ratio
either into the VIT group or into the control group in
each of the nine injuries separately. Patients of the VIT
group will receive a short instruction regarding the use
of the already-accredited and CE-certified VIT system.
Afterwards, the VIT system will be applied to the foot in
the case of a lower extremity fracture or to the hand in
the case of an upper extremity injury. The therapy inter-
val of pneumatic compression will be chosen as recom-
mended by the company: 24 h a day in the preoperative
period and 6 to 8 h in the postoperative period. In the
control group the injured extremity will be splinted and
elevated for 24 h a day in the preoperative period. In the
postoperative period the time of elevation is recom-
mended according to the soft tissue swelling. In both
groups the duration of the therapy (pneumatic compres-
sion or elevation) will be documented during the daily
study visits. In all patients, no further antiswelling inter-
ventions, such as lymphatic drainage, will be applied.
The primary investigator will perform an interim ana-
lysis regarding the presence of adverse events and drop-
outs after the inclusion of the first 30 patients. In case of
the occurrence of any adverse event related to the study,
the responsible local Ethics Committee will be informed
to decide whether the study can by continued or not. No
forms of nonignorable clustering regarding the primary
outcome parameter have been detected during planning
of the study.
Evaluation
The primary outcome parameter (time to operability)
will be assessed day-to-day by one of two independent
experienced orthopedic senior consultants, who will de-
fine whether the soft tissue permits definite surgical
treatment of the fracture, irrespective of other reasons
that do not allow surgical treatment. These independent
examiners are not involved with the design of the study.
The definition of operability is decided by these blinded
examiners based on two basic rules: (1) that there is
crumpling of the skin at the surgical side and (2) that su-
turing of the skin without tension will be possible after
definitive operative treatment. For the assessment of the
primary outcome parameter, the time from injury to the
first day of operability will be documented regardless of
the time of definitive surgical treatment.
The time schedule of the study and the primary and
secondary outcome parameters and respective measure-
ments are shown in Table 1 and Fig. 2. The final follow-
up will be obtained 14 (±4) days after the patients have
been formally discharged.
Sample size
The prior assumptions for sample size calculation are
based on the results of Caschman et al. and Keehan et
al. and assume a decrease of the mean time from injury
to operability of 2 days in the VIT group compared to
the control group [10, 20]. Allowing for an assumed
standard deviation of 2 days and that 15% of the patients
in each group will be lost to follow-up then a total of 20
patients (17 patients + 3 patients assumed to dropout) is
required in each group to ensure an 80% chance of sig-
nificant detection (at the 5% level based on a two-sided t
test). The sample size calculation based on the results of
Caschman et al. and Keehan et al. can be used for three
of the nine injury types: the calcaneal fracture, the ankle
fracture and the tibial pilon fracture. In these three in-
jury types 40 patients will be included, respectively. For
the other six injury types a sample size calculation is not
possible due to a lack of data in the medical literature.
Therefore, in the other anatomical regions a sample size
calculation was obtained from the institutional data from
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Table 1 Please check if we have captured the tables correctly.Study outcome measures of the Vascular Impulse Technology (VIT) study
Item Outcome measurement Measurement point Primary/secondary
outcome parameter
Operability Time from injury to operability (days) Daily visit preoperatively Primary
Soft tissue swelling Girth measurements of the injured and the
uninjured contralateral extremity (cm)
Daily visit pre and postoperatively and
14 days after submission
Secondary
Pain level Visual Analog Scale (VAS) Daily visit pre and postoperatively and
14 days after submission
Secondary
Pain medication Substance and dosage of painkillers Daily visit pre and postoperatively and
14 days after submission
Secondary
Complications Detailed description of complications Daily visit pre and postoperatively and
14 days after submission
Secondary
Revision surgeries Detailed description of revision surgeries Daily visit postoperatively and 14 days
after submission
Secondary
Duration of total hospital stay Days At the day of submission Secondary
Fig. 2 Content for the schedule of enrollment, intervention and assessments for each of the nine injury types (SPIRIT figure)
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the year 2014 (Table 2). It is estimated that 30% of the
patients can be recruited after checking the inclusion
and exclusion criteria. Taking the institutional data from
the year 2014 into account, 30 patients with distal radius
fracture, 16 patients with elbow dislocation, 14 patients
distal humerus fracture, 30 patients with proximal hu-
merus fracture, 40 patients with tibial head fracture and
30 patients with tibia shaft fracture will be included in
the study. The number of patients who will be random-
ized in each of the nine injury types is shown in Table 2.
In total, 280 patients will be included in nine separate
studies according to the nine different injury types. The
study length for recruitment is expected to be 2 years.
The follow-up period is 14 days after discharge from
hospital treatment.
Statistical methods
Descriptive statistics (mean, standard deviation, median,
interquartile range, absolute and relative frequencies)
will be calculated to characterize the study population. A
separate analysis for each of the nine injury types will be
performed. The primary outcome parameter, the time
from injury to operability (in days) will be assessed using
a t test. In addition, a sensitivity analysis with the non-
parametric Mann-Whitney U test will be performed. In
addition, Kaplan-Meier survival curves for descriptive
analysis of the primary outcome parameter will be visu-
alized. For continuous secondary variables a t test will
be applied, possible differences of categorical endpoints
will be analyzed using chi-square tests. A p value < 0.05
is considered as statistically significant. Univariate and
multivariate regression analyses will be performed to
investigate the influence of parameters, such as age,
gender and affected side, on the outcome. The primary
outcome parameter will be assessed day-to-day by one
of two independent experienced orthopedic senior
consultants. To validate the agreement of the assessment
of the two examiners, the exact agreement regarding the
binary variable (operability: yes or not) on 10 consecutive
patients will be assessed each day from randomization to
definitive surgical treatment. The exact agreement of both
examiners regarding the primary outcome parameter
should be at least 90%.
The intention-to-treat principle will be adopted: pa-
tients will be analyzed according to their initial treat-
ment group in case of crossover to the other group. A
sensitivity analysis with a per-protocol analysis will be
performed to assess the robustness of the results.
Handling missing data
The extent of missing data for the primary outcome
should be limited, as it is recorded in the daily visits of
the study patients. The data entry must be completed
electronically in the data management system before dis-
charge and research nurses should make every effort to
collect this. Where these time-critical data are missing,
multiple imputation methods may be considered to in-
form a sensitivity analysis.
Documentation
All protocol-required information collected during the
trial must be entered by the investigator, or designated
representative, in the Case Report Form (CRF). A paper-
based CRF will be used to collect the data. The investi-
gator, or designated representative, should complete the
CRF pages as soon as possible after information is col-
lected, preferably on the day of the study visit. Any out-
standing entries must be completed immediately after
the final examination. An explanation should be given
for all missing data.
The completed CRF must be reviewed and signed
by the investigator or by an authorized subinvestiga-
tor named in the trial protocol. The CRF data will
be transferred to an electronic data management sys-
tem (REDCap). Completeness, validity and plausibil-
ity of data are examined by the management system
which thereby generates queries. The investigator or
the designated representatives are obliged to clarify
or explain the queries. At the end of the trial, the
principal investigator will retain the originals of all
CRFs. The data will be managed and analyzed in ac-
cordance with the appropriate standard operating
procedures (SOP).
Table 2 Sample size calculation
Injury Number of patients
in 2014 at the study
center
Number of patients
included in the
planned study
Calcaneal fracture
(intra-articular)
119 40a
Ankle fractures: type 44B/C 106 40a
Tibial pilon fracture: type
43B/C
64 40a
Distal radius fracture:
type 23C
102 30b
Tibial shaft fractures 100 30b
Elbow dislocations (simple
and complex)
55 16b
Distal humeral fractures:
type 13B/C
46 14b
Proximal humeral fractures 99 30b
Tibial head fractures:
type 41B/C
138 40b
Total 280
asample size calculation are based on the results of Caschman et al. [20];
bsample size calculation based on the treated patients in 2014 in the
study center
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Assessment of safety
According to the international principles of the Good
Clinical Practice (ICH-GCP) the term “adverse event”
covers any clinically relevant sign, symptom, syndrome
or illness that appears or worsens in a subject during the
period of observation in the clinical trial and that may
impair the subject’s wellbeing.
Adverse events fall into the categories nonserious and
serious. Nonserious adverse events will not be docu-
mented in the VIT study. From the beginning of the
study until the regular end of trial at 14 days (±4)
follow-up or until premature withdrawal of the patient,
all serious adverse events (SAE) must be documented on
a “Serious Adverse Event Form” that is available in the
Investigator Site File. Any other complications that are
considered as clinically relevant by the investigator
should be documented in free text.
Serious adverse events must be reported by the attend-
ing physician to the principal investigator within 1 day
after the SAE becomes known. The principal investigator
is responsible for registering all SAEs and for checking
incoming SAEs for completeness, correctness and
plausibility. In the event of an SAE, the principal investi-
gator will inform the local Ethics Committee without
delay. Analysis of safety-related data is performed with
respect to frequency of SAE in both treatment groups.
Criteria for termination of the trial
The principal investigator has the right to terminate the
trial and to remove all trial material from the trial center
at any time in consultation with the trial statistician and
the local Ethics Committee. Reasons that may require
trial termination include potential health hazards caused
by the study intervention as indicated by the prevalence
or severity of adverse events, unsatisfactory patient en-
rollment with respect to quality or quantity, or where
data recording is severely inaccurate or incomplete. New
external evidence may also necessitate termination of
the trial.
Ethics and trial registration
This study will be carried out according to the Helsinki
Declaration in its latest version dated 2004, the Medical
Association’s professional code of conduct and the
international principles of the Good Clinical Practice
(ICH-GCP). The trial will also be carried out in compli-
ance with national legal and regulatory requirements.
Additionally, the medical secrecy and the German
Federal Data Protection Act will be observed. Patients
will receive complete oral and written information about
the trial from a physician and a written Informed
Consent Form must be signed.
Before the start of the trial, the clinical trial protocol,
the Informed Consent Form and any other appropriate
documents will be submitted to the Independent Ethics
Committee (IEC). The trial was registered in the German
Clinical Trial Register (http://www.germanctr.de) with a
unique identification number (No. DRKS00010510) on 17
July 2016. Protocol modifications will be made in agree-
ment with the local IEC. The trial management is commit-
ted to writing a scientific publication even if the trial is
stopped early. The design of the trial and the trial results
will be published and the authorship will be assigned by
the trial management. Please see Additional file 1 for the
SPIRIT Checklist.
Discussion
If there are two or more treatment options for one clin-
ical condition a randomized controlled trial with a clin-
ically relevant endpoint should determine, which is more
beneficial to the patient [25].
Standard therapy for the treatment of preoperative
swelling includes inpatient bed rest and elevation of the
injured extremity to reduce swelling to an acceptable
level for operative treatment [11]. Alternatively, an
impulse foot- and hand-pump system (such as the VIT
system) can be used to reduce edema of the injured ex-
tremity [11, 20]. However, prospective controlled trials
are still lacking and the information regarding the effect-
iveness of the impulse foot- and hand-pump devices is
sparse [23].
The proposed study will compare standard treatment
and the use of an impulse foot- and hand-pump system
(VIT system) for the lower and upper extremities in a
prospective, randomized controlled trial setting. In
agreement with previous medical literature the time
from injury to operability was chosen as primary out-
come parameter as this is mainly influenced by pre-
operative swelling of the soft tissue [10, 20]. The
primary study objective of this trial will be to answer the
question as to whether using the VIT system will reduce
the time from injury to surgery compared to the stand-
ard therapy. The results will have a direct implication as
preoperative swelling often precludes surgery within the
first week after injury. According to the preliminary data
from Caschman et al. and Keehan at al. we hypothesize
that patients using the Vascular Impulse Technology
(VIT) system can receive surgical treatment 2 days earl-
ier than patients with elevation due to faster reduction
of soft tissue swelling [10, 20]. Interventions, such as
lymphatic drainage, compressive dressings or cryother-
apy, have not been added to eliminate the occurrence of
selection bias.
A potential study limitation is the risk of performance
bias. The primary outcome measurement is based on the
assessment of a team of two independent but non-
blinded examiners. Even if the assessment is based on
prespecified rules, the decision (operability?: yes or no)
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is primarily based on the experience of the examiner.
Therefore, a validation of the exact agreement on the
rating of both examiners on 10 consecutive patients will
be performed. The primary outcome parameter (time
from injury to operability) was chosen for clinical rele-
vance in accordance to previous studies.
Trial status
The study is about to start enrolling participants.
Additional file
Additional file 1: SPIRIT 2013 Checklist: recommended items to address
in a clinical trial protocol and related documents*. (PDF 113 kb)
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